This site requires Javascript.

Please enable Javascript before proceeding:

Firefox

  1. In the FireFox address bar, type about:config.
  2. Look for the javascript.enabled setting.
  3. Set it to true by right-clicking and pressing toggle.

Internet Explorer

  1. On the Tools menu, click Internet Options, then click the Security tab.
  2. Click the Internet Zone.
  3. If you do not have to customize your Internet security settings, click Default Level. Then do step 4.
  4. If you have to customize your Internet security settings, follow these steps:
    a. Click Custom Level.
    b. In the Security Settings - Internet Zone dialog box, click Enable for Active Scripting in the Scripting section.
  5. Click the Back button to return to the previous page, and then click the Refresh button to run scripts.

Chrome

  1. In the Chrome address bar, type chrome://settings/content/javascript.
  2. Adjust the toggle so that javascript is allowed.
  3. Close the Settings tab and Refresh the page.

 

Sponsored Symposia

Sanofi Industry Symposium

Thursday March 26 12:15-1:45pm Porter Room

Navigating cGVHD Care Across Borders: Insights into US vs. Canadian Treatment Strategies

Dr. Dennis Kim Dr. Corey Cutler

Moderated by Dr. Jonas Mattsson

Objectives:

  • Compare treatment objectives in 3rd line as per CTTC guidelines vs. US (EBMT) guidelines.
  • Focused discussion on fibrotic manifestations (eyes, lungs, skin, and combinations).
  • Explore QoL in GVHD patients - its meaning and role in treatment decisions.
Lilly Industry Symposium

Friday March 27 7:30-8:30am Porter Room

Double Exposed CLL/SLL in Practice: Treatment Patterns, Outcomes, and Clinical Decision Points

Dr. Meghan C. Thompson

Objectives:

  • Describe real world clinical management of patients with double exposed CLL/SLL who have received both a covalent BTK inhibitor and a BCL 2 inhibitor.
  • Compare therapeutic approaches used following exposure to covalent BTK inhibitors and BCL 2 inhibitors, highlighting real world clinical considerations./li>
  • Apply current evidence-based treatment options to clinical decision making for patients with double exposed CLL/SLL, incorporating emerging data and unmet needs in this setting.
Novartis Industry Symposium

Friday March 27 1:15-2:45pm Porter Room

Navigating the future of CML management: tailoring care for better outcomes

Dr. Ehab L. Atallah

Moderated by Dr. Dennis Kim

Objectives:

  • Understand how first-line treatment selection can influence disease control, quality of life and the potential to achieve treatment-free remission in CML.
  • Discuss the importance of tolerability in maintaining long-term treatment adherence.
  • Evaluate how real-world evidence complements clinical trial data by informing treatment patterns, discontinuation, and outcomes in CML.
  • Review key Ontario-based clinical and research initiatives and their role in addressing current evidence gaps in CML management.
Daiichi-Sankyo Industry Symposium

Saturday March 28 7:30-8:30 am Porter Room

Optimizing Transplant and Maintenance Strategies in Newly Diagnosed FLT3-ITD Positive AML

Dr. Dennis Kim

Moderated by Dr. Jonas Mattsson

Objectives:

  • Characterize FLT3 ITD positive AML and its relapse risk, including after allogeneic hematopoietic cell transplantation (allo HCT)
  • Differentiate who is and is not a candidate for allo HCT
  • Evaluate and implement FLT3 inhibitor (FLT3i) maintenance in transplant and non transplant settings

Support Provided By:

Event Dates and Times

Thursday March 26, 2026
8:00 am - 5:30 pm EDT

Friday March 27, 2026
7:30 am - 5:30 pm EDT

Saturday March 28, 2026
8:00 am - 1:30 pm EDT

Event Location

Courtyard Toronto Downtown Hotel
475 Yonge St,
Toronto, ON
M4Y 1X7 

Information & Assistance

Conference Services
conferences@uhn.ca